{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:15:18Z","timestamp":1793319318595,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"DOI":"10.1007\/s11883-025-01376-x","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T11:26:57Z","timestamp":1767698817000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Highlights of Cardiovascular Disease Prevention Studies Presented at the 2025 American Heart Association Scientific Sessions"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5145-8626","authenticated-orcid":false,"given":"Ali Bin","family":"Abdul Jabbar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Unaiza","family":"Naeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalsoom","family":"Zulfiqar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahnoor","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Inam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Hinkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Mannan Khan","family":"Minhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Slipczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chayakrit","family":"Krittanawong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh K.","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim S.","family":"Virani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"issue":"1","key":"1376_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-025-01313-y","volume":"27","author":"V Junaid","year":"2025","unstructured":"Junaid V, Hinkamp C, Hamid A, Abdul Jabbar AB, Minhas AMK, Inam M, et al. Highlights of cardiovascular disease prevention studies presented at the 2025 American College of Cardiology Conference. Curr Atheroscler Rep. 2025;27(1):67. https:\/\/doi.org\/10.1007\/s11883-025-01313-y.","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"1376_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-025-01355-2","volume":"27","author":"AB Abdul Jabbar","year":"2025","unstructured":"Abdul Jabbar AB, Naeem U, Zulfiqar K, Ahmed S, Hinkamp C, Inam M, et al. Highlights of cardiovascular disease prevention studies presented at the 2025 European Society of Cardiology Conference. Curr Atheroscler Rep. 2025;27(1):107. https:\/\/doi.org\/10.1007\/s11883-025-01355-2.","journal-title":"Curr Atheroscler Rep"},{"issue":"11","key":"1376_CR3","first-page":"e596","volume":"140","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: A report of the American college of Cardiology\/American heart association task force on clinical practice guidelines. Circulation. 2019;140(11):e596\u2013646.","journal-title":"Circulation"},{"issue":"7","key":"1376_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11883-020-00846-8","volume":"22","author":"A Hussain","year":"2020","unstructured":"Hussain A, Ballantyne CM, Saeed A, Virani SS. Triglycerides and ASCVD risk reduction: recent insights and future directions. Curr Atheroscler Rep. 2020;22(7):25.","journal-title":"Curr Atheroscler Rep"},{"key":"1376_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2024.100648","volume":"18","author":"A Filtz","year":"2024","unstructured":"Filtz A, Parihar S, Greenberg GS, Park CM, Scotti A, Lorenzatti D, et al. New approaches to triglyceride reduction: is there any hope left? Am J Prev Cardiol. 2024;18:100648.","journal-title":"Am J Prev Cardiol"},{"issue":"22","key":"1376_CR6","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1001\/jama.2020.22258","volume":"324","author":"SJ Nicholls","year":"2020","unstructured":"Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 2020;324(22):2268\u201380. https:\/\/doi.org\/10.1001\/jama.2020.22258.","journal-title":"JAMA"},{"issue":"21","key":"1376_CR7","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","volume":"387","author":"AD Pradhan","year":"2022","unstructured":"Pradhan AD, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, et al. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med [Internet]. 2022;387(21):1923\u201334.","journal-title":"N Engl J Med [Internet]"},{"issue":"21","key":"1376_CR8","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1056\/NEJMe2213208","volume":"387","author":"SS Virani","year":"2022","unstructured":"Virani SS. The fibrates story - a tepid end to a PROMINENT drug. N Engl J Med. 2022;387(21):1991\u20132.","journal-title":"N Engl J Med"},{"key":"1376_CR9","doi-asserted-by":"crossref","unstructured":"Marston NA, Bergmark BA, Alexander VJ, Prohaska TA, Kang YM, Moura FA et al. Olezarsen for managing severe hypertriglyceridemia and pancreatitis risk. N Engl J Med. 2025.","DOI":"10.1056\/NEJMoa2512761"},{"issue":"18","key":"1376_CR10","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"22","key":"1376_CR11","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107.","journal-title":"N Engl J Med"},{"key":"1376_CR12","doi-asserted-by":"crossref","unstructured":"Bohula EA, Marston NA, Bhatia AK, De Ferrari GM, Leiter LA, Nicolau JC et al. Evolocumab in patients without a previous myocardial infarction or stroke. N Engl J Med. 2025.","DOI":"10.1056\/NEJMoa2514428"},{"issue":"8","key":"1376_CR13","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1161\/CIRCOUTCOMES.122.009787","volume":"16","author":"AM Navar","year":"2023","unstructured":"Navar AM, Kolkailah AA, Gupta A, Gillard KK, Israel MK, Wang Y, et al. Gaps in guideline-based lipid-lowering therapy for secondary prevention in the United States: a retrospective cohort study of 322\u2005153 patients. Circ Cardiovasc Qual Outcomes. 2023;16(8):533\u201343.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"1376_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100624","volume":"29","author":"KK Ray","year":"2023","unstructured":"Ray KK, Haq I, Bilitou A, Manu MC, Burden A, Aguiar C, et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. The Lancet Regional Health. 2023;29:100624.","journal-title":"The Lancet Regional Health"},{"issue":"1","key":"1376_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/14779072.2020.1717335","volume":"18","author":"D Mahtta","year":"2020","unstructured":"Mahtta D, Rodriguez F, Jneid H, Levine GN, Virani SS. Improving adherence to cardiovascular guidelines: realistic transition from paper to patient. Expert Rev Cardiovasc Ther. 2020;18(1):41\u201351.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"18","key":"1376_CR16","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/j.jacc.2022.02.042","volume":"79","author":"SS Virani","year":"2022","unstructured":"Virani SS, Ballantyne CM, Petersen LA. Guideline-Concordant Statin therapy use in secondary prevention: should the medical community wait for divine intervention? J Am Coll Cardiol. 2022;79(18):1814\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1376_CR17","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1161\/CIRCULATIONAHA.122.063372","volume":"148","author":"DG Johns","year":"2023","unstructured":"Johns DG, Campeau LC, Banka P, Bautmans A, Bueters T, Bianchi E, et al. Orally bioavailable macrocyclic peptide that inhibits binding of PCSK9 to the low density lipoprotein receptor. Circulation. 2023;148(2):144\u201358.","journal-title":"Circulation"},{"issue":"16","key":"1376_CR18","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.jacc.2023.02.018","volume":"81","author":"CM Ballantyne","year":"2023","unstructured":"Ballantyne CM, Banka P, Mendez G, Garcia R, Rosenstock J, Rodgers A, et al. Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616. J Am Coll Cardiol. 2023;81(16):1553\u201364.","journal-title":"J Am Coll Cardiol"},{"issue":"45","key":"1376_CR19","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"BG Nordestgaard","year":"2013","unstructured":"Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European atherosclerosis society. Eur Heart J. 2013;34(45):3478\u2013a3490.","journal-title":"Eur Heart J"},{"issue":"12","key":"1376_CR20","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1001\/jamacardio.2021.3508","volume":"6","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Pletcher MJ, Vittinghoff E, Clemons AM, Jacobs DR, Allen NB, et al. Association between cumulative low-density lipoprotein cholesterol exposure during young adulthood and middle age and risk of cardiovascular events. JAMA Cardiol. 2021;6(12):1406\u201313.","journal-title":"JAMA Cardiol"},{"key":"1376_CR21","doi-asserted-by":"crossref","unstructured":"Ballantyne CM, Gellis L, Tardif JC, Banka P, Navar AM, Asprusten EA et al. Efficacy and safety of oral PCSK9 inhibitor enlicitide in adults with heterozygous Familial hypercholesterolemia: A randomized clinical trial. JAMA. 2025;e2520620.","DOI":"10.1001\/jama.2025.20620"},{"issue":"7","key":"1376_CR22","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1001\/jamacardio.2017.1421","volume":"2","author":"JD Bundy","year":"2017","unstructured":"Bundy JD, Li C, Stuchlik P, Bu X, Kelly TN, Mills KT, et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol. 2017;2(7):775\u201381.","journal-title":"JAMA Cardiol"},{"issue":"11","key":"1376_CR23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11886-021-01584-2","volume":"23","author":"AJ Hare","year":"2021","unstructured":"Hare AJ, Patel MS, Volpp K, Adusumalli S. The Role of Behavioral Economics in Improving Cardiovascular Health Behaviors and Outcomes. Curr Cardiol Rep [Internet]. 2021;23(11):153.","journal-title":"Curr Cardiol Rep [Internet]"},{"key":"1376_CR24","unstructured":"Ostchega Y, Fryar CD, Nwankwo T, Nguyen DT. Hypertension prevalence among adults aged 18 and over: united States, 2017\u20132018. NCHS Data Brief. 2020;(364):1\u20138."},{"issue":"13","key":"1376_CR25","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1001\/jama.2018.13467","volume":"320","author":"G Howard","year":"2018","unstructured":"Howard G, Cushman M, Moy CS, Oparil S, Muntner P, Lackland DT, et al. Association of clinical and social factors with excess hypertension risk in black compared with white US adults. JAMA. 2018;320(13):1338\u201348.","journal-title":"JAMA"},{"issue":"1","key":"1376_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1056\/NEJM200101043440101","volume":"344","author":"FM Sacks","year":"2001","unstructured":"Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. DASH-Sodium collaborative research group. N Engl J Med. 2001;344(1):3\u201310.","journal-title":"N Engl J Med"},{"key":"1376_CR27","unstructured":"Access to Affordable and Nutritious Food-Measuring and Understanding Food Deserts and Their Consequences. Report to Congress | Economic Research Service [Internet]. [cited 2025 Nov 15]. Available from: https:\/\/www.ers.usda.gov\/publications\/pub-details?pubid=42729"},{"key":"1376_CR28","unstructured":"Juraschek SP, Col H, Ferro K, Turkson-Ocran RAN, Cluett JL, Davis RB et al. DASH-Patterned groceries and effects on blood pressure: the GoFresh randomized clinical trial. JAMA. 2025;e2521112."},{"issue":"10159","key":"1376_CR29","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1016\/S0140-6736(18)32225-6","volume":"392","author":"GBD 2017 Risk Factor Collaborators","year":"2018","unstructured":"GBD 2017 Risk Factor Collaborators. Global, regional, and National comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet Lond Engl. 2018;392(10159):1923\u201394.","journal-title":"Lancet Lond Engl"},{"key":"1376_CR30","doi-asserted-by":"publisher","first-page":"e071952","DOI":"10.1136\/bmj-2022-071952","volume":"380","author":"M Zhang","year":"2023","unstructured":"Zhang M, Shi Y, Zhou B, Huang Z, Zhao Z, Li C, et al. Prevalence, awareness, treatment, and control of hypertension in China, 2004-18: findings from six rounds of a national survey. BMJ. 2023;380:e071952.","journal-title":"BMJ"},{"issue":"10","key":"1376_CR31","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1038\/s41591-022-01974-1","volume":"28","author":"C Razo","year":"2022","unstructured":"Razo C, Welgan CA, Johnson CO, McLaughlin SA, Iannucci V, Rodgers A, et al. Effects of elevated systolic blood pressure on ischemic heart disease: a burden of proof study. Nat Med. 2022;28(10):2056\u201365.","journal-title":"Nat Med"},{"issue":"16","key":"1376_CR32","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"KGMM Alberti","year":"2009","unstructured":"Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, Lung, and blood Institute; American heart association; world heart federation; international atherosclerosis Society; and international association for the study of obesity. Circulation. 2009;120(16):1640\u20135.","journal-title":"Circulation"},{"key":"1376_CR33","doi-asserted-by":"publisher","first-page":"E24","DOI":"10.5888\/pcd14.160287","volume":"14","author":"JX Moore","year":"2017","unstructured":"Moore JX, Chaudhary N, Akinyemiju T. Metabolic syndrome prevalence by Race\/Ethnicity and sex in the united States, National health and nutrition examination Survey, 1988\u20132012. Prev Chronic Dis. 2017;14:E24.","journal-title":"Prev Chronic Dis"},{"key":"1376_CR34","unstructured":"Trends in the Prevalence of Metabolic Syndrome in the United States. 2011\u20132016 - PubMed [Internet]. [cited 2025 Nov 15]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32573660\/"},{"issue":"1175","key":"1376_CR35","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1093\/postmj\/qgad008","volume":"99","author":"X Liang","year":"2023","unstructured":"Liang X, Or B, Tsoi MF, Cheung CL, Cheung BMY. Prevalence of metabolic syndrome in the united States National health and nutrition examination survey 2011-18. Postgrad Med J. 2023;99(1175):985\u201392.","journal-title":"Postgrad Med J"},{"key":"1376_CR36","unstructured":"Powell LH, Berkley-Patton J, Drees BM, Karavolos K, Lohse B, Masters KS et al. Lifestyle Intervention for Sustained Remission of Metabolic Syndrome. JAMA Intern Med [Internet]. 2025 Nov 9 [cited 2025 Nov 15];e255900. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12598583\/"},{"issue":"1","key":"1376_CR37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0899-3289(88)80009-9","volume":"1","author":"JR Hughes","year":"1988","unstructured":"Hughes JR, Amori G, Hatsukami DK. A survey of physician advice about caffeine. J Subst Abuse. 1988;1(1):67\u201370.","journal-title":"J Subst Abuse"},{"issue":"12","key":"1376_CR38","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1056\/NEJMoa2204737","volume":"388","author":"GM Marcus","year":"2023","unstructured":"Marcus GM, Rosenthal DG, Nah G, Vittinghoff E, Fang C, Ogomori K, et al. Acute effects of coffee consumption on health among ambulatory adults. N Engl J Med. 2023;388(12):1092\u2013100.","journal-title":"N Engl J Med"},{"issue":"9","key":"1376_CR39","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1001\/jamainternmed.2021.3616","volume":"181","author":"EJ Kim","year":"2021","unstructured":"Kim EJ, Hoffmann TJ, Nah G, Vittinghoff E, Delling F, Marcus GM. Coffee consumption and incident tachyarrhythmias: reported behavior, Mendelian Randomization, and their interactions. JAMA Intern Med. 2021;181(9):1185\u201393.","journal-title":"JAMA Intern Med"},{"issue":"17","key":"1376_CR40","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1093\/eurjpc\/zwac189","volume":"29","author":"D Chieng","year":"2022","unstructured":"Chieng D, Canovas R, Segan L, Sugumar H, Voskoboinik A, Prabhu S, et al. The impact of coffee subtypes on incident cardiovascular disease, arrhythmias, and mortality: long-term outcomes from the UK biobank. Eur J Prev Cardiol. 2022;29(17):2240\u20139.","journal-title":"Eur J Prev Cardiol"},{"key":"1376_CR41","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12916-015-0447-8","volume":"13","author":"SC Larsson","year":"2015","unstructured":"Larsson SC, Drca N, Jensen-Urstad M, Wolk A. Coffee consumption is not associated with increased risk of atrial fibrillation: results from two prospective cohorts and a meta-analysis. BMC Med. 2015;13:207.","journal-title":"BMC Med"},{"issue":"12","key":"1376_CR42","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1177\/2047487320908385","volume":"28","author":"C Krittanawong","year":"2021","unstructured":"Krittanawong C, Tunhasiriwet A, Wang Z, Farrell AM, Chirapongsathorn S, Zhang H, et al. Is caffeine or coffee consumption a risk for new-onset atrial fibrillation? A systematic review and meta-analysis. Eur J Prev Cardiol. 2021;28(12):e13\u20135.","journal-title":"Eur J Prev Cardiol"},{"issue":"4","key":"1376_CR43","first-page":"448","volume":"30","author":"M Cheng","year":"2014","unstructured":"Cheng M, Hu Z, Lu X, Huang J, Gu D. Caffeine intake and atrial fibrillation incidence: dose response meta-analysis of prospective cohort studies. Can J Cardiol. 2014;30(4):448\u201354.","journal-title":"Can J Cardiol"},{"key":"1376_CR44","doi-asserted-by":"crossref","unstructured":"Wong CX, Cheung CC, Montenegro G, Oo HH, Pe\u00f1a IJ, Tang JJ et al. Caffeinated coffee consumption or abstinence to reduce atrial fibrillation: the DECAF randomized clinical trial. JAMA. 2025;e2521056.","DOI":"10.1001\/jama.2025.21056"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01376-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-025-01376-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01376-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T22:01:42Z","timestamp":1767736902000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-025-01376-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1376"],"URL":"https:\/\/doi.org\/10.1007\/s11883-025-01376-x","relation":{},"ISSN":["1534-6242"],"issn-type":[{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No animal or human subjects by the authors were used in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"SSV has received research funding from the National Institutes of Health, the US Department of Veterans Affairs, the NIHR UK, the Tahir and Jooma Family, and the Asharia Family. LZ reports grants from Amgen and Philips, and personal fees from Elsevier during the conduct of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"7"}}